Adalimumab eye injections vs under-skin shots for uveitis
Treatments studied
Part of Eyes & vision clinical trials.
This trial compares two forms of the same medicine (adalimumab) to treat non-infectious uveitis, an inflammation inside the eye. It aims to see which delivery method works better to control active inflammation and protect vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-infectious uveitis that affects the back or middle of the eye (not just the front).
- Your uveitis is “active” right now, even though you’ve been on prednisone at least 10 mg/day for at least 2 weeks (or a similar steroid).
- You’ve had a documented good response to steroid tablets in the past.
- If you take prednisone 10 mg or more, your dose has not been changed for the last 14 days.
- Your tuberculosis (TB) test is negative, or if it’s positive you’ve taken anti-TB medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two medicines, mycophenolate mofetil and adalimumab, to help control eye inflammation (uveitis) and reduce the need for steroids. It is for people who still have active inflammation despite taking a steroid medication like prednisone.
This trial tests whether people with chronic uveitis (eye inflammation) who have been stable on adalimumab (a biologic medicine) for at least 24 weeks can safely reduce their dose. The goal is to see if a lower dose can still control the inflammation while reducing side effects and costs.
This study tests a drug called adalimumab, which helps calm the immune system, when added to the steroid medicine you may already be taking. It aims to see if this combination is safe and works better for people with Behçet's disease that affects the back of the eye and has recently flared up.
This trial tests a different way of giving a steroid injection for eye swelling (macular edema) caused by uveitis. It is for people whose swelling hasn't improved with a standard steroid injection behind the eye.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.